Biology-oriented drug synthesis (BIODS): In vitro β-glucuronidase inhibitory and in silico studies on 2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethyl aryl carboxylate derivatives
-
Add time:08/06/2019 Source:sciencedirect.com
Current study is based on the biology-oriented drug synthesis (BIODS) of 2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethyl aryl carboxylate derivatives 1–26, by treating metronidazole with different aryl and hetero-aryl carboxylic acids in the presence of 1,1′-carbonyl diimidazole (CDI) as a coupling agent. Structures of all synthetic derivatives were confirmed with the help of various spectroscopic techniques such as EI-MS, 1H -NMR and 13C NMR. CHN elemental analyses were also found in agreement with the calculated values. Synthetic derivatives were evaluated to check their β-glucuronidase inhibitory activity which revealed that except few derivatives, all demonstrated good inhibition in the range of IC50 = 1.20 ± 0.01–60.30 ± 1.40 μM as compared to the standard d-saccharic acid 1,4-lactone (IC50 = 48.38 ± 1.05 μM). Compounds 1, 3, 4, 6, 9–19, and 21–24 were found to be potent analogs and showed superior activity than standard. Limited structure-activity relationship is suggested that the molecules having electron withdrawing groups like NO2, F, Cl, and Br, were displayed better activity than the compounds with electron donating groups such as Me, OMe and BuO. To verify these interpretations, in silico study was also performed, a good correlation was observed between bioactivities and docking studies.
We also recommend Trading Suppliers and Manufacturers of 1-(1-METHYL-1H-IMIDAZOL-2-YL)-PIPERAZINE (cas 113049-35-7). Pls Click Website Link as below: cas 113049-35-7 suppliers
Prev:Ion-pair charge transfer complex with near-IR absorption: Synthesis, crystal structure and properties of [Hb]2[Cu(mnt)2] (Hb = 1-(4-((1H-imidazol-1-yl)methyl)benzyl)-1H-imidazol-3-ium)
Next:Synthesis, spectroscopic and DNA binding ability of CoII, NiII, CuII and ZnII complexes of Schiff base ligand (E)-1-(((1H-benzo[d]imidazol-2-yl)methylimino)methyl)naphthalen-2-ol. X-ray crystal structure determination of cobalt (II) complex) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Synthesis of new 5-((2-(substituted phenoxymethyl)-1H-benzo[d]imidazol-1-yl)methyl)-1,3,4-oxadiazole-2-thiol: A novel class of potential antibacterial and antifungal agents08/10/2019
- Copper(II) and zinc(II) as metal-carboxylate coordination complexes based on (1-methyl-1H-benzo[d]imidazol-2-yl) methanol derivative: Synthesis, crystal structure, spectroscopy, DFT calculations and antioxidant activity08/09/2019
- Importance of 5/6-aryl substitution on the pharmacological profile of 4ʹ-((2-propyl-1H-benzo[d]imidazol-1-yl)methyl)-[1,1ʹ-biphenyl]-2-carboxylic acid derived PPARγ agonists08/08/2019
- Synthesis, spectroscopic and DNA binding ability of CoII, NiII, CuII and ZnII complexes of Schiff base ligand (E)-1-(((1H-benzo[d]imidazol-2-yl)methylimino)methyl)naphthalen-2-ol. X-ray crystal structure determination of cobalt (II) complex08/07/2019
- Ion-pair charge transfer complex with near-IR absorption: Synthesis, crystal structure and properties of [Hb]2[Cu(mnt)2] (Hb = 1-(4-((1H-imidazol-1-yl)methyl)benzyl)-1H-imidazol-3-ium)08/05/2019
- Biology-oriented drug synthesis (BIODS) of 2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethyl aryl ether derivatives, in vitro α-amylase inhibitory activity and in silico studies08/04/2019
- Syntheses, crystal structures and luminescent properties of two salts with 2-((1H-imidazol-1-yl)methyl)-1H-benzimidazole08/03/2019


